{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T11:14:51Z","timestamp":1759058091847},"reference-count":20,"publisher":"Hindawi Limited","issue":"5","license":[{"start":{"date-parts":[[2012,3,6]],"date-time":"2012-03-06T00:00:00Z","timestamp":1330992000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2012,3,6]],"date-time":"2012-03-06T00:00:00Z","timestamp":1330992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1111\/j.1365-2710.2012.01336.x","type":"journal-article","created":{"date-parts":[[2012,3,6]],"date-time":"2012-03-06T08:51:30Z","timestamp":1331023890000},"page":"571-577","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson\u2019s disease"],"prefix":"10.1155","volume":"37","author":[{"given":"N.","family":"Hattori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2012,3,6]]},"reference":[{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0091-3057(91)90603-Y","article-title":"Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist","volume":"38","author":"Eden","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/sj.bjp.0702673","article-title":"Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells","volume":"127","author":"Coldwell","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2165\/00023210-199912050-00006","article-title":"Dopamine D3 receptors: relevance for drug treatment of Parkinson\u2019s disease","volume":"12","author":"Levant","year":"1999","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB4|cit4","first-page":"R50","volume-title":"Therapeutic drugs","year":"1999"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1211\/0022357001774895","article-title":"Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats","volume":"52","author":"Reavill","year":"2000","journal-title":"J Pharm Pharmacol"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/0023210-200923010-00006","article-title":"Ropinirole prolonged release - in advanced Parkinson\u2019s disease","volume":"23","author":"Weber","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.1365-2125.1998.t01-1-00704.x","article-title":"Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients","volume":"45","author":"Brefel","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.clinthera.2007.12.010","article-title":"Steady-state pharmacokinetics properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson\u2019s disease","volume":"29","author":"Thompson","year":"2007","journal-title":"Clin Ther"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/004982599238696","article-title":"Disposition of ropinirole in animals and man","volume":"29","author":"Ramji","year":"1999","journal-title":"Xenobiotica"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/00003088-200039040-00001","article-title":"Clinical pharmacokinetics of ropinirole","volume":"39","author":"Kaye","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB11|cit11","first-page":"840","article-title":"In vitro identification of the p450 enzymes responsible for the metabolsim of ropinirole","volume":"25","author":"Bloomer","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1067\/mcp.2002.126173","article-title":"A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test","volume":"72","author":"Saruwatari","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/clpt.1991.176","article-title":"Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities","volume":"50","author":"Kalow","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00008571-199206000-00003","article-title":"Determination of CYP1A2 and NAT2 Phenotypes in human populations by analysis of caffeine urinary metabolites","volume":"2","author":"Bulter","year":"1992","journal-title":"Pharmacogenetics"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/00007691-199610000-00011","article-title":"The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate","volume":"18","author":"Bartoli","year":"1996","journal-title":"Ther Drug Monit"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/mds.20602","article-title":"Suboptimal medication adherence in Parkinson\u2019s disease","volume":"20","author":"Grosset","year":"2005","journal-title":"Mov Disord"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/mds.20041","article-title":"Drug adherence in Parkinson\u2019s disease","volume":"19","author":"Leopold","year":"2004","journal-title":"Mov Disord"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/mds.21313","article-title":"Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson\u2019s disease: STRONG study","volume":"22","author":"Mizuno","year":"2007","journal-title":"Mov Disord"},{"key":"10.1111\/j.1365-2710.2012.01336.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1185\/03007990802387130","article-title":"Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson\u2019s disease: A randomized, double-blind, non-inferiority crossover study","volume":"24","author":"Stocchi","year":"2008","journal-title":"Curr Med Res Opin"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2012.01336.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2012.01336.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2012.01336.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:04:29Z","timestamp":1671818669000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2012.01336.x"}},"subtitle":["PK of ropinirole in Japanese patients"],"short-title":[],"issued":{"date-parts":[[2012,3,6]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2012.01336.x","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3,6]]}}}